Alpha Tau (DRTS) Medical announced an approval from the U.S. Food and Drug Administration, FDA, of an Investigational Device Exemption IDE, supplement to the IDE previously announced on Jan 27, 2025, which had approved a clinical study examining the combination of Alpha DaRT and first-line chemotherapy in 12 patients with newly diagnosed metastatic pancreatic cancer, allowing expansion of the clinical trial to a broader group of pancreatic cancer patients. The IDE supplement allows the Company to include an additional cohort for locally advanced pancreatic cancer patients, and to increase the number of each cohort to 15 patients, for a total of 30 patients across the two cohorts, at up to 10 U.S. clinical trial sites.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRTS:
- Alpha Tau Medical Reports Promising Interim Data and Regulatory Milestones in Cancer Trials
- Alpha Tau shares interim data across multiple clinical trials at R&D Update Day
- Alpha Tau receives IDE from FDA for study evaluating Alpha DaRT, chemo combo
- Alpha Tau announces interim data from pembrolizumab combination trial
- Alpha Tau to Present Groundbreaking Cancer Therapy Data at ASCO Symposium
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue